Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.

Saved in:
Bibliographic Details
Title: Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.
Authors: Metz M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.; Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany., Sussman G; Division of Allergy and Clinical Immunology, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada., Gagnon R; Service d'Allergie et Immunologie, Département de Médecine, Centre Hospitalier Universitaire de Québec, Quebec City, Québec, Canada., Staubach P; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Tanus T; Kern Allergy Medical Clinic Inc., Bakersfield, CA, USA., Yang WH; Ottawa Allergy Research Corporation, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada., Lim JJ; Genentech, Inc., South San Francisco, CA, USA., Clarke HJ; Genentech, Inc., South San Francisco, CA, USA., Galanter J; Genentech, Inc., South San Francisco, CA, USA., Chinn LW; Genentech, Inc., South San Francisco, CA, USA., Chu T; Genentech, Inc., South San Francisco, CA, USA., Teterina A; Hoffman-LaRoche Limited, Missisauga, Ontario, Canada., Burgess T; Genentech, Inc., South San Francisco, CA, USA., Haddon DJ; Genentech, Inc., South San Francisco, CA, USA., Lu TT; Genentech, Inc., South San Francisco, CA, USA., Maurer M; Dermatological Allergology, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany. marcus.maurer@charite.de.; Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Berlin, Germany. marcus.maurer@charite.de.
Source: Nature medicine [Nat Med] 2021 Nov; Vol. 27 (11), pp. 1961-1969. Date of Electronic Publication: 2021 Nov 08.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-021-01537-w